Beda Pharmaceuticals: Analysis results in the middle of the study period of nsatini hydrochloric acid eXalt3.

Guide: The results showed that in patients with ALK-positive non-small cell lung cancer (NSCLC) treated with Ensatinib, the no-progression survival (mPFS) was significantly longer than in patients treated with cratinib.
On August 8, 2020, the results of the new generation of ALK inhibitor Enshatinib (Ensartinib, X-396) International Multi-Center Clinical Research (eXalt3) Phase III Clinical Research (eXalt3) at the World Lung Cancer Conference (ILCWCWC) jointly developed by Beida PharmaceuticalCoG Inc. (the "Company") and its holding subsidiary Xcovery Holdings, Inc. ("Xcovercompany Company") ("Xcovery Company") jointly developed the results of the New Generation Of Alk-Based Inhibitor Ensartinib (Ensartinib, X-396) International Multi-Center Clinical Research (eXalt3) Phase III Clinical Research.
results showed that alK-positive non-small cell lung cancer (NSCLC) patients treated with Ensatinib had significantly longer progression-free survival (mPFS) than those treated with cratinib.
an outlinkini eXalt3 study enrolled a total of 290 ALK-positive NSCLC patients and was randomly assigned to the ensatinib or krysatinib treatment group.
data as of July 1, 2020, progress events accounted for 73% of the pre-set progress events in the final analysis, as assessed by the Blind Independent Review Committee (BIRC).
data showed a significant statistical difference between the median progression-free survival (mPFS) of the ensatinib treatment group and 12.7 months for the treatment group with krythininib.
Survival Analysis (K-M Curve) shows that at 36 months after treatment, less than 40 percent of patients in the Ensatinib group progressed, while 75 percent of the patients in the Krystinib group progressed.
for now, the eXalt3 study will continue to follow up on patients being treated.
, in alK-positive non-small cell lung cancer patients, Enshatinib significantly prolonged progression-free survival, with good safety, and is a new choice for first-line treatment.
based on the eXalt3 study, Beida Pharmaceuticals will be preparing for the listing of first-line indications in China and the United States, and Ensatini will be the first innovative drug to be listed globally for Beida Pharmaceuticals.
.